Dapoxetine Hydrochloride CAS # 119356-77-3

Dapoxetine Hydrochloride CAS # 119356-77-3

Dapoxetine, sold as Priligy (amongst other brands), is the first compound explicitly formulated for the treatment of premature ejaculation (PE) in men aged 18 to 64 years. Dapoxetine acts by inhibiting the transporter of serotonin, increasing the action of serotonin in the post-synaptic cleft to postpone ejaculation. Dapoxetine was initially formulated as an antidepressant as part of the Selective Serotonin Reuptake Inhibitor (SSRI) family.

However, Dapoxetine is absorbed and quickly eliminated in the body, unlike other SSRIs. It is appropriate for the treatment of PE because of its rapid reaction, but not as an antidepressant.

Treat erectile dysfunction and male premature ejaculation.

Other SSRIs, such as Fluoxetine, Paroxetine, Sertraline, Fluvoxamine, and Citalopram, have been used as clinical drugs for the treatment of PE due to the lack of formal approval for PE treatment in the US and some other countries.

Waldinger’s meta analysis reveals that, compared to three to eight times when Dapoxetine is used, the usage of these traditional antidepressants raises IELT by around 2-9 times. However in order to maintain meaningful effectiveness, these SSRIs must be taken regularly, and the long half-life raises the risk of drug accumulation and as a result, increasing adverse effects, such as reducing sexual libido and triggering erectile dysfunction. Dapoxetine, on the other hand, is an SSRI that is fast-acting. Within a few hours, it is quickly absorbed and removed from the body. This beneficial pharmacokinetics minimizes the likelihood of accumulation of the drug in the body and thereby, decreases the side effects.